Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant vs Sequential COVID-19 and Influenza Vaccination
NCT06020118Phase 4Completed
- Sponsor
- Duke University
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of elasomeran, influenza vaccine (cell-based) in coronavirus disease 2019 (COVID-19), influenza, sponsored by Duke University. Started Sep 2023; status: completed.
02
Drugs
elasomeraninfluenza vaccine (cell-based)
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06020118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020118.